Search
Bevantolol
go.drugbank.com/drugs/DB01295InvestigationalMechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. … Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.
Categories: Cytochrome P-450 Substrates, Adrenergic alpha-1 Receptor AntagonistsSynonyms: 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol, 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-olLaropiprant
go.drugbank.com/drugs/DB11629ApprovedWithdrawnLaropiprant is an ingredient in the EMA-withdrawn product Pelzont.
Mixtures: CORDAPTIVE®Categories: Heterocyclic Compounds, 2-RingTozorakimab
go.drugbank.com/drugs/DB16473InvestigationalTozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. … moderate-to-severe asthma), NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in
Synonyms: ) L123>M (121)) CDR-IMGT [8.8.19] (26-33.51-58.97-1, Immunoglobulin G1, anti-(human interleukin 33) (human monoclonal MEDI3506 γ1-chain), disulfide with human monoclonal MEDI3506 λ-chain, dimerInterferon alfacon-1
go.drugbank.com/drugs/DB00069ApprovedWithdrawnInterferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. … Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon.
Categories: Interferon Type I, interferon alfacon-1Synonyms: IFN Alfacon-1, IFN-Con1DA-697b
go.drugbank.com/drugs/DB06001ExperimentalDA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.
FP-1096
go.drugbank.com/drugs/DB05310ExperimentalFP1096 reduced the painful symptoms of endometriosis in trial subjects with very minimal side effect.
AZD2315
go.drugbank.com/drugs/DB06540ExperimentalThe drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase
Synonyms: L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, ACETATE (1:2), L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, DIACETATEPazufloxacin
go.drugbank.com/drugs/DB11774InvestigationalPazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).
Categories: Topoisomerase II Inhibitors, 4-QuinolonesRDEA806
go.drugbank.com/drugs/DB05228InvestigationalRDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.